Dr. Leen Kawas, CEO of EIT Pharma, Highlights on EASL Congress 2026
Summary
EIT Pharma used the EASL Congress 2026 stage to present new analyses from its lonafarnib program for chronic hepatitis D. The company highlighted Dr. Leen Kawas’s leadership as CEO and her broader biotechnology and investment background. The announcement also emphasized the D-LIVR trial, the largest clinical study in chronic hepatitis D, and its oral late-stage treatment profile. EIT Pharma says it has been engaging with the FDA and preparing a path toward commercialization. The company expects to share more data with the medical community in the coming months.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected